A single dose of the monoclonal-antibody AZD7442 (combination of tixagevimab and cilgavimab) has been shown to be safe and effective as prophylaxis against COVID-19 infection in high risk individuals who tested positive for COVID-19. 

Held on April 19, 2022, Tuesday Night Rheumatology: Controversies in PsA, featured a lively and informative panel discussion, moderated by Dr. Jack Cush.

The PsA Expert panelists included:

Patients with axial spondyloarthritis (SpA) got more bang for their exercise buck in a randomized trial when they had good opinions about their workout program, with better persistence with exercise at 1 year relative to a control group, researchers said.

The results of the DIETA trial showed that dietary changes may control psoriatic arthritis (PsA) disease activity, independent of weight loss.  

A recording of this week’s Tuesday Night Rheumatology is now available. This outstanding webinar featured a robust discussion of the EXCEED study and Discover-2 trial, with Drs. Philip Mease, Peter Nash, Jack Cush and Rachel Tate.

Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic. 

Pediatric patients with moderate-to-severe plaque psoriasis obtained significant improvement in disease status for as long as 2 years with the interleukin (IL)-17A inhibitor ixekizumab (Taltz), long-term follow-up from a randomized trial showed.

While treat-to-target (T2T) is commonly advocated in gout management, it is unknown if T2T (or more intensive T2T) may result in less bony erosions in gout.

The Canadian Rheumatology Association’s (CRA) Telehealth Working Group (TWG) has developed a series of best practice statements for the virtual care in adult and pediatric rheumatology patients.

Arthritis & Rheumatology has publish an ACR Subcommittee report on how the COVID-19 pandemic affected fellows and their training. 

Tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis were linked with a lower risk of Alzheimer's disease and related dementia, but only in people with cardiovascular disease, data from the DREAM (Drug Repurposing for Effective Alzheimer's Medicines) study showed.

Dr. Jack Cush reviews the news and journal articles from the past week and discusses the use of fibroscan in RA, steroid hip injections in OA and famous quotes from a famous cardiologist.

A single ultrasound guided intra-articular hip corticosteroid injection can be quite effective in patients with hip osteoarthritis (OA).

Watch this outstanding and informative Tuesday Nite Rheumatology, held on April 5th, 2022 which featured a Patient Perspectives panel discussion, hosted by Dr. Jack Cush.

PsA Panelists included:

- Tena Brown

- Christine Lindsay

- Ashley Krivohlavek

A recent study analyzed the impact of dactylitis in disease-modifying antirheumatic drug (DMARD)-naive early psoriatic arthritis (PsA) and found that DMARD-naive PsA patients with dactylitis (dactylitic PsA) have a greater burden of disease than those without dactylitis. 

An evaluation of a common psoriasis drug's effect on one cardiometabolic risk factor instead showed a favorable impact on a different one.